ES2603086T3 - Uso de la daptomicina - Google Patents

Uso de la daptomicina Download PDF

Info

Publication number
ES2603086T3
ES2603086T3 ES06006697.4T ES06006697T ES2603086T3 ES 2603086 T3 ES2603086 T3 ES 2603086T3 ES 06006697 T ES06006697 T ES 06006697T ES 2603086 T3 ES2603086 T3 ES 2603086T3
Authority
ES
Spain
Prior art keywords
daptomycin
dose
treatment
hours
need
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES06006697.4T
Other languages
English (en)
Inventor
Frederick B. Oleson Jr.
Francis P. Tally
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cubist Pharmaceuticals LLC
Original Assignee
Cubist Pharmaceuticals LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26798675&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2603086(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Cubist Pharmaceuticals LLC filed Critical Cubist Pharmaceuticals LLC
Application granted granted Critical
Publication of ES2603086T3 publication Critical patent/ES2603086T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)

Abstract

La daptomicina, para su uso en el tratamiento de una infección bacteriana en un paciente humano en necesidad del mismo, en el que una dosis para dicho tratamiento es de 10 mg/kg de daptomicina, en el que dicha dosis se administra repetidamente en un intervalo de administración de una vez cada 24 horas.

Description

Uso de la daptomicina
examinados en cada uno de cuatro perros para un total de
ES06006697.4T 1998-09-25 1999-09-24 Uso de la daptomicina Expired - Lifetime ES2603086T3 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US10182898P 1998-09-25 1998-09-25
US101828P 1998-09-25
US12575099P 1999-03-24 1999-03-24
US125750P 1999-03-24

Publications (1)

Publication Number Publication Date
ES2603086T3 true ES2603086T3 (es) 2017-02-23

Family

ID=26798675

Family Applications (2)

Application Number Title Priority Date Filing Date
ES99949913T Expired - Lifetime ES2259845T3 (es) 1998-09-25 1999-09-24 Uso de la daptomicina.
ES06006697.4T Expired - Lifetime ES2603086T3 (es) 1998-09-25 1999-09-24 Uso de la daptomicina

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ES99949913T Expired - Lifetime ES2259845T3 (es) 1998-09-25 1999-09-24 Uso de la daptomicina.

Country Status (26)

Country Link
US (2) US6468967B1 (es)
EP (2) EP1674107B8 (es)
JP (4) JP4184607B2 (es)
KR (2) KR20010075327A (es)
CN (2) CN1530136A (es)
AT (1) ATE322280T1 (es)
AU (1) AU764348B2 (es)
BR (1) BR9914051A (es)
CA (1) CA2344318C (es)
CY (3) CY1105556T1 (es)
DE (3) DE122006000049I1 (es)
DK (2) DK1115417T3 (es)
ES (2) ES2259845T3 (es)
HK (1) HK1040363B (es)
HU (1) HU230656B1 (es)
IS (2) IS5890A (es)
LU (1) LU91254I2 (es)
NL (1) NL300232I2 (es)
NO (1) NO20011454L (es)
NZ (1) NZ510690A (es)
PL (2) PL203689B1 (es)
PT (2) PT1674107T (es)
RU (1) RU2363489C9 (es)
SI (2) SI1115417T1 (es)
TR (1) TR200100841T2 (es)
WO (1) WO2000018419A2 (es)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU230656B1 (hu) 1998-09-25 2017-06-28 Cubist Pharmaceuticals Llc Daptomicin alkalmazása
BR0017026A (pt) 1999-12-15 2003-01-07 Cubist Pharm Inc Lipeptìdeos como agentes antibacterianos
US6696412B1 (en) 2000-01-20 2004-02-24 Cubist Pharmaceuticals, Inc. High purity lipopeptides, Lipopeptide micelles and processes for preparing same
WO2002059145A1 (en) * 2000-12-18 2002-08-01 Cubist Pharmaceuticals, Inc. Methods for preparing purified lipopeptides
JP2004525108A (ja) * 2000-12-18 2004-08-19 キュービスト ファーマスーティカルズ インコーポレイテッド 精製リポペプチドの調製方法
US20060014674A1 (en) 2000-12-18 2006-01-19 Dennis Keith Methods for preparing purified lipopeptides
EP1932853A1 (en) 2001-08-06 2008-06-18 Cubist Pharmaceutical Inc. Novel depsipeptides and process for preparing same
WO2004017925A2 (en) * 2002-08-23 2004-03-04 Genome Therapeutics Corporation Methods and reagents for preventing bacteremias
US20050277581A1 (en) * 2002-11-18 2005-12-15 Vicuron Pharmaceuticals Inc. Dalbavancin compositions for treatment of bacterial infections
US20060074014A1 (en) * 2002-11-18 2006-04-06 Vicuron Pharmaceuticals Inc. Dalbavancin compositions for treatment of bacterial infections
US20050220862A1 (en) * 2004-03-31 2005-10-06 Bernstein Joel E Compositions with reduced hepatotoxicity
US20060004185A1 (en) * 2004-07-01 2006-01-05 Leese Richard A Peptide antibiotics and peptide intermediates for their prepartion
US20060014677A1 (en) * 2004-07-19 2006-01-19 Isotechnika International Inc. Method for maximizing efficacy and predicting and minimizing toxicity of calcineurin inhibitor compounds
US20080051326A1 (en) * 2004-11-12 2008-02-28 Alexander Dylan C Antiinfective Lipopeptides
US8546423B2 (en) 2005-05-18 2013-10-01 Mpex Pharmaceuticals, Inc. Aerosolized fluoroquinolones and uses thereof
US7838532B2 (en) * 2005-05-18 2010-11-23 Mpex Pharmaceuticals, Inc. Aerosolized fluoroquinolones and uses thereof
US20070238630A1 (en) * 2006-03-29 2007-10-11 Phillips Douglas H Subcutaneous skin cleanser
EP2018864A1 (en) * 2007-07-23 2009-01-28 Biomet Deutschland GmbH Pharmaceutical composition, substrate comprising a pharmaceutical composition, and use of a pharmaceutical composition
CA2713989A1 (en) * 2008-03-04 2009-09-11 Elan Pharma International Limited Stable liquid formulations of anti-infective agents and adjusted anti-infective agent dosing regimens
EP3338791B1 (en) 2008-07-17 2019-09-18 Acorda Therapeutics, Inc. Therapeutic dosing of a neuregulin in the treatment or prophylaxis of heart failure
DE102008046610A1 (de) * 2008-09-09 2010-03-11 Biomet Deutschland Gmbh Verwendung einer pharmazeutischen Zusammensetzung zur lokalen Infektionstherapie sowie Medizinprodukt
AU2009302478B2 (en) 2008-10-07 2015-09-03 Horizon Orphan Llc Aerosol fluoroquinolone formulations for improved pharmacokinetics
CN102325532B (zh) 2008-10-07 2015-06-17 Mpex医药有限公司 用于减轻肺部炎症的左氧氟沙星吸入剂
WO2010048630A1 (en) 2008-10-24 2010-04-29 Los Angeles Biomedical Reserch Institute At Harbor-Ucla Medical Center Anti-infective hydroxy-phenyl-benzoates and methods of use
NZ594019A (en) * 2008-12-22 2013-08-30 Cubist Pharm Inc Novel antibacterial agents for the treatment of gram positive infections
WO2010075416A1 (en) 2008-12-23 2010-07-01 Biosource Pharm, Inc. Antibiotic compositions for the treatment of gram negative infections
CA2767614C (en) * 2009-07-13 2019-01-15 Cempra Pharmaceuticals Inc. Fusidic acid dosing regimens for treatment of bacterial infections
US8450300B2 (en) * 2009-07-13 2013-05-28 Cempra Pharmaceuticals Inc. Fusidic acid dosing regimens for treatment of bacterial infections
LT2473170T (lt) 2009-09-04 2019-10-10 Horizon Orphan Llc Aerozolizuoto levofloksacino panaudojimas cistinės fibrozės gydymui
CA2781666C (en) 2009-11-23 2017-02-21 Cubist Pharmaceuticals, Inc. Lipopeptide compositions and related methods
US8247394B2 (en) 2010-06-02 2012-08-21 Cempra Pharmaceuticals Inc. Methods of treating urethritis and related infections using fusidic acid
US8415307B1 (en) 2010-06-23 2013-04-09 Biosource Pharm, Inc. Antibiotic compositions for the treatment of gram negative infections
WO2013059610A1 (en) * 2011-10-20 2013-04-25 Trius Therapeutics, Inc. Therapeutic combination of daptomycin and protein synthesis inhibitor antibiotic, and methods of use
TW201343645A (zh) 2012-03-30 2013-11-01 Cubist Pharm Inc １，３，４－□二唑及１，３，４－噻二唑β－內醯胺酶抑制劑
PL4066849T3 (pl) * 2012-09-11 2025-06-16 Hospira Australia Pty Ltd Preparaty daptomycyny i ich zastosowania
CN103006562B (zh) * 2013-01-21 2014-09-17 西南大学 达托霉素醇质体制剂
WO2014152332A1 (en) 2013-03-15 2014-09-25 Melinta Therapeutics, Inc. Methods of treating infections in overweight and obese patients using antibiotics
US11667674B2 (en) 2016-04-08 2023-06-06 Versitech Limited Antibacterial cyclic lipopeptides
US10647746B2 (en) 2016-04-08 2020-05-12 Versitech Limited Antibacterial cyclic lipopeptides
JP2019515007A (ja) * 2016-05-13 2019-06-06 スペロ ポテンシエーター インコーポレイテッドＳｐｅｒｏ Ｐｏｔｅｎｔｉａｔｏｒ， Ｉｎｃ． 新規カチオン性ペプチドｓｐｒ７４１による、抗生物質活性の増強
CN114788814B (zh) * 2021-01-26 2023-10-13 浙江创新生物有限公司 一种高稳定性的注射用达托霉素组合物及其制备方法和其应用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE32333E (en) 1978-10-16 1987-01-20 Eli Lilly And Company A-21978 Antibiotics and process for their production
USRE32455E (en) 1978-10-16 1987-07-07 Eli Lilly And Company A-21978 antibiotics and process for their production
US4524135A (en) 1982-05-21 1985-06-18 Eli Lilly And Company A-21978C cyclic peptides
US4482487A (en) 1982-05-21 1984-11-13 Eli Lilly And Company A-21978C cyclic peptides
USRE32311E (en) 1982-05-21 1986-12-16 Eli Lilly And Company Derivatives of A-21978C cyclic peptides
USRE32310E (en) 1982-05-21 1986-12-16 Eli Lilly And Company Derivatives of A-21978C cyclic peptides
US4537717A (en) 1982-05-21 1985-08-27 Eli Lilly And Company Derivatives of A-21978C cyclic peptides
US4885243A (en) 1984-10-09 1989-12-05 Eli Lilly And Company Process for producing A-21978C derivatives
US4800157A (en) 1985-09-09 1989-01-24 Eli Lilly And Company Process for producing the A-21978C antibiotics
ZA883887B (en) 1987-06-10 1990-02-28 Lilly Co Eli Chromatographic purification process
US4874843A (en) 1987-12-03 1989-10-17 Eli Lilly And Company Chromatographic purification process
CA2011365A1 (en) * 1989-03-06 1990-09-06 Eugene L. Inman Diluent formulation for daptomycin
FR2755857B1 (fr) * 1996-11-19 1998-12-24 Rhone Poulenc Rorer Sa Compositions pharmaceutiques stabilisees, a base de quinupristine et de dalfopristine et leur preparation
FR2772272B1 (fr) * 1997-12-16 2000-01-14 Rhone Poulenc Rorer Sa Compositions pharmaceutiques a base de dalfopristine et de quinupristine et leur preparation
HU230656B1 (hu) 1998-09-25 2017-06-28 Cubist Pharmaceuticals Llc Daptomicin alkalmazása
US9393093B2 (en) 2008-02-18 2016-07-19 Covidien Lp Clip for implant deployment device

Also Published As

Publication number Publication date
JP2006335773A (ja) 2006-12-14
RU2004106569A (ru) 2005-08-10
EP1115417B1 (en) 2006-04-05
PL203689B1 (pl) 2009-11-30
NL300232I1 (nl) 2006-09-01
CN1348382A (zh) 2002-05-08
ATE322280T1 (de) 2006-04-15
AU6268799A (en) 2000-04-17
ES2259845T3 (es) 2006-10-16
PT1674107T (pt) 2016-12-07
RU2363489C9 (ru) 2010-03-20
NO20011454L (no) 2001-05-25
NL300232I2 (nl) 2007-01-02
CN1530136A (zh) 2004-09-22
CA2344318C (en) 2006-07-04
HK1040363B (en) 2007-01-26
IS8807A (is) 2009-03-10
JP4184607B2 (ja) 2008-11-19
WO2000018419A3 (en) 2000-07-06
HK1040363A1 (en) 2002-06-07
KR20100051735A (ko) 2010-05-17
DE122006000049I2 (de) 2007-11-08
CA2344318A1 (en) 2000-04-06
DE122006000049I1 (de) 2007-01-04
RU2363489C2 (ru) 2009-08-10
HUP0103874A2 (hu) 2002-02-28
CY2006003I1 (el) 2009-11-04
AU764348B2 (en) 2003-08-14
DK1115417T3 (da) 2006-07-31
CN1150029C (zh) 2004-05-19
CY2006003I2 (el) 2009-11-04
JP2002525335A (ja) 2002-08-13
SI1674107T1 (sl) 2017-01-31
EP1674107A2 (en) 2006-06-28
JP2004339238A (ja) 2004-12-02
NZ510690A (en) 2002-10-25
PT1115417E (pt) 2006-07-31
DK1674107T3 (en) 2016-12-19
LU91254I2 (fr) 2006-08-28
DE69930758T2 (de) 2007-04-26
CY1105556T1 (el) 2010-07-28
PL206091B1 (pl) 2010-06-30
NO20011454D0 (no) 2001-03-22
US6468967B1 (en) 2002-10-22
SI1115417T1 (sl) 2006-08-31
DE69930758D1 (de) 2006-05-18
KR20010075327A (ko) 2001-08-09
IS5890A (is) 2001-03-14
JP2003321389A (ja) 2003-11-11
US6852689B2 (en) 2005-02-08
HUP0103874A3 (en) 2002-09-30
BR9914051A (pt) 2001-06-19
EP1674107A8 (en) 2006-10-04
WO2000018419A2 (en) 2000-04-06
US20020142948A1 (en) 2002-10-03
EP1674107A3 (en) 2012-06-20
EP1674107B1 (en) 2016-08-24
EP1674107B8 (en) 2017-01-25
PL348328A1 (en) 2002-05-20
CY1118334T1 (el) 2017-06-28
EP1115417A2 (en) 2001-07-18
HU230656B1 (hu) 2017-06-28
TR200100841T2 (tr) 2002-01-21

Similar Documents

Publication Publication Date Title
NO955361L (no) Organiske aerogeler
BR0009016A (pt) Composição de apomorfina e sildenafil
AR026610A1 (es) Un derivado pirrolidinacetamida solo o en combinacion para tratamiento de desordenes del sistema nervioso central
ES2191192T3 (es) Tienopirimidinas.
DK0586621T3 (da) Linsidomin til behandling af erektile dysfunktioner
PA8504401A1 (es) Compuestos farmaceuticamente activos
ES2132105T3 (es) 2-aminometil-cromanos como principios activos en farmacos para el tratamiento de enfermedades del sistema nervioso central.
ES2164040T1 (es) Uso de agonistas del sitio de union de la glicina o de inhibidores de la absorcion de la glicina para el tratamiento de trastornos neuropsiquiatricos.
EA200101156A1 (ru) ЛЕКАРСТВЕННЫЕ КОМПОЗИЦИИ НОВОГО ТИПА НА ОСНОВЕ ОБЛАДАЮЩИХ ХОЛИНЕРГИЧЕСКИМ ДЕЙСТВИЕМ СОЕДИНЕНИЙ И β-МИМЕТИКОВ
AR016798A1 (es) Uso de una cepa de lactobacillus para la elaboracion de un medicamento
BRPI0408236A (pt) método para radiofluoração, composto, composição radiofarmacêutica, uso de um composto, e, métodos para gerar uma imagem de um corpo humano ou animal e para monitorar o efeito de tratamento de um corpo humano ou animal com um medicamento para combater uma condição associada com cáncer
BRPI0108977B8 (pt) compostos azacíclicos, composição farmacêutica e uso de um composto ou sal farmaceuticamente aceitável do mesmo
DK0998287T3 (da) Anvendelse af levobupivacain
EA200401317A1 (ru) Композиции и способы дозирования липосом определенных размеров для лечения или предотвращения заболевания
NO20032027L (no) Effektive antitumorbehandlinger
BRPI0413974A (pt) combinação, método de tratamento de cáncer em um animal de sangue quente, composição farmacêutica, e, uso de uma combinação
NO20055880L (no) Memantin orale doseringsformer
ES2083597T3 (es) Preparacion farmaceutica para el tratamiento del tiempo de coagulacion prolongado.
ES2135342B1 (es) Uso del raloxifeno o una sal o salvato del mismo en la preparacion de un medicamento para prevenir el cancer de mama.
GEP20043227B (en) 5HT1 Antagonists for Antidepressant Therapy
BR0009380A (pt) Tratamento de câncer melhorado comtemozolomida
AR027394A1 (es) Uso de mirtazapina para el tratamiento de trastornos del sueno
ATE297732T1 (de) Kombinationstherapie zur behandlung von herzinsuffizienz
AR048318A1 (es) Formulaciones de matriz orales que comprenden licarbazepina
AR047154A1 (es) Tratamiento del insomnio en pacientes humanos administrandoles una cantidad diaria de gaboxadol